A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC

Study Overview

• Status: Not yet recruiting
• Conditions: Non Small Cell Lung Cancer
• Intervention / Treatment: Drug: Firmonertinib; Drug: Firmonertinib/pemetrexed/Carboplatin; Drug: Firmonertinib/pemetrexed/Carboplatin/Bevacizumab

Detailed Description

For locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR-sensitive mutations (Ex19del/L858R), we evaluated the clinical value of first-line adaptive treatment with firmonertinib guided by ctDNA EGFRm and minimal residual disease (MRD) status. Patients underwent gene testing either through tissue or blood samples (when tissue was not accessible). Patients with EGFR-sensitive mutations (Ex19del/L858R) also underwent Onco Snoar 172 gene testing. These patients were treated with firmonertinib monotherapy, and their clinical response was assessed through imaging after 6 weeks of treatment. Patients with primary resistance (PD) were excluded from the study, while other patients provided blood samples for gene testing. If patients' plasma did not harbor EGFR-sensitive mutations and did not exhibit other gene mutations, they continued to receive firmonertinib monotherapy. If other mutations were present, chemotherapy was added to firmonertinib. If patients had plasma EGFR-sensitive mutations, they were further grouped. Patients without ctDNA clearance and without gene mutations continued to receive oral firmonertinib, while those with other gene mutations received oral firmonertinib combined with chemotherapy. Patients with ctDNA clearance and PIK3CA, PTEN, RB1 mutations were treated with firmonertinib combined with chemotherapy. Patients with other gene mutations or no mutations received firmonertinib and chemotherapy combined with anti-angiogenic drugs. Patients with clearance and TP53 mutations received firmonertinib plus anti-angiogenic therapy. This study aimed to explore the efficacy of first-line adaptive treatment with firmonertinib guided by gene status in locally advanced or metastatic EGFR-mutant NSCLC.

• Study Type: Interventional
• Enrollment (Estimated): 154
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yueyin Pan; Phone Number: 13805695536; Email: panyueyin@ustc.edu.cn

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China
      • Anhui Provincial Cancer Hospital
      • Contact: Yueyin Pan; Phone Number: 13805695536; Email: panyueyin@ustc.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Sign a written informed consent before implementing any trial-related procedures;
• At least 18 years of age;
• Have histologically or cytologically confirmed non-squamous non-small cell lung cancer.
• Confirmed presence of EGFR-sensitive mutation-positive by tumor histology, cytology, hematology, or pleural effusion supernatant;
• ECOG score of 0-1;
• According to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), there must be at least one measurable lesion on imaging. Lesions located within the previous radiation field that have proven progression can be considered measurable;
• Life expectancy >3 months at Day 1;
• Patients newly diagnosed with locally advanced (IIIB-IIIC), metastatic, or recurrent (stage IV) lung cancer according to the 9th edition of the TNM classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer; not suitable for treatment with surgery or radiotherapy;
• Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;
• Not previously treated with anti-angiogenic drugs/chemotherapy;
• Brain metastasis patients are allowed to be enrolled, as long as they meet the following conditions:

• Sufficient organ function, and the subjects must meet the following laboratory criteria:

  1. Absolute neutrophil count (ANC) ≥1.5x10^9/L without the use of granulocyte colony-stimulating factor in the past 14 days;
  2. Platelets ≥100×10^9/L without blood transfusion in the past 14 days;
  3. Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days;
  4. Total bilirubin ≤1.5×upper limit of normal (ULN);
  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (subjects with liver metastasis are allowed to have ALT or AST ≤5×ULN);
  6. Serum creatinine ≤1.5×ULN and creatinine clearance rate (calculated using the Cockcroft-Gault formula) ≥60 ml/min;
  7. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;
  8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled;
  9. myocardial enzyme profile within the normal range (subjects with simple laboratory abnormalities that the investigator comprehensively judges to have no clinical significance are also allowed to be enrolled);
• For female subjects of childbearing age, urine or serum pregnancy tests must be conducted within 3 days before the first dose of study drug (on Day 1 of Cycle 1) and the results must be negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing age females are defined as those who have been postmenopausal for at least 1 year, or have undergone surgical sterilization or hysterectomy;
• If there is a risk of pregnancy, all subjects (regardless of gender) must use contraception with an annual failure rate of less than 1% throughout the treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of study drug).

Exclusion Criteria:

• The pathology is small cell lung cancer (SCLC), including lung cancer with a mixture of SCLC and non-small cell lung cancer (NSCLC);

• The patient has received the following treatments:

  1. received systemic anti-tumor therapy within 3 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal medicine therapy with anti-tumor indications), etc.;
  2. received any investigational drug therapy within 4 weeks before treatment;
  3. received high-dose immunosuppressive drugs (systemic glucocorticoids exceeding 10mg/day of prednisone or its equivalent dose) within 4 weeks before treatment;
  4. received attenuated live vaccines within 4 weeks before treatment (or plans to receive attenuated live vaccines during the study period);
  5. underwent major surgery (such as thoracotomy, thoracotomy, or Kaifu surgery) within 4 weeks before treatment, or has unhealed surgical wounds, ulcers, or fractures.
• Subjects with clinically uncontrollable pleural/peritoneal effusion (not requiring drainage of effusion or showing no significant increase in effusion after 3 days of cessation of drainage) may be enrolled;
• Subjects with a history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid treatment, or any evidence of clinically active ILD;
• Subjects who have received chest radiotherapy exceeding 30 Gy within 6 months prior to treatment or palliative radiotherapy of 30 Gy or less within 7 days prior to treatment (palliative radiotherapy for bone or intracranial lesions is allowed);
• Subjects who have experienced active autoimmune diseases requiring systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment;
• Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
• Subjects who have not fully recovered from toxicity and/or complications caused by any intervention prior to the start of treatment (i.e., grade ≤1 or baseline, excluding fatigue or alopecia);
• Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive);
• Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copy number greater than the upper limit of normal in the laboratory department of the research center); Note: Subjects with hepatitis B who meet the following criteria may also be enrolled: 1) HBV viral load <1000 copies/ml (200 IU/ml) prior to the first dose, and subjects should receive anti-HBV treatment throughout the study drug treatment period to avoid viral reactivation; 2) For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), prophylactic anti-HBV treatment is not required, but close monitoring for viral reactivation is necessary.
• Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the detection limit);
• Subjects who have received a live vaccine within 30 days prior to the first dose (Cycle 1, Day 1); Note: Inactivated virus vaccine for seasonal influenza administered via injection is allowed within 30 days prior to the first dose; however, attenuated live influenza vaccine administered intranasally is not allowed.
• Pregnant or lactating women;

• Subjects with any severe or uncontrollable systemic diseases, such as:

  1. significant and symptomatically severe abnormalities in rhythm, conduction, or morphology on resting electrocardiogram, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation;
  2. unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification of ≥ 2;
  3. myocardial infarction within 6 months prior to enrollment;
  4. poorly controlled blood pressure (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg);
  5. history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to the first dose, or current clinically active interstitial lung disease;
  6. active tuberculosis;
  7. active or uncontrollable infections requiring systemic treatment;
  8. clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction;
  9. liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  10. poorly controlled diabetes (fasting blood glucose (FBG) >10 mmol/L);
  11. urine routine test indicating proteinuria ≥++ and confirmed 24-hour urine protein quantitation >1.0 g;
  12. subjects with mental disorders and unable to cooperate with treatment; subjects with medical history or disease evidence, treatment, or laboratory test values that may interfere with trial results, hinder the subject's full participation in the study, or other situations deemed unsuitable for enrollment by the investigator; subjects deemed by the investigator to have other potential risks and are not suitable to participate in this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A1; firmonertinib	Drug: Firmonertinib; 80mg QD
Experimental: Arm A2; firmonertinib combined with chemotherapy	Drug: Firmonertinib/pemetrexed/Carboplatin; Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by firmonertinib daily with pemetrexed maintenance every 3 weeks.
Experimental: Arm B1; firmonertinib combined with chemotherapy	Drug: Firmonertinib/pemetrexed/Carboplatin; Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by firmonertinib daily with pemetrexed maintenance every 3 weeks.
Experimental: Arm B2; firmonertinib combined with chemotherapy and antiangiogenic drugs	Drug: Firmonertinib/pemetrexed/Carboplatin/Bevacizumab; Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by firmonertinib daily with pemetrexed and bevacizumab maintenance every 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Progression-free survival (PFS)	through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall Survival (OS)	through study completion, an average of 4 years
Objective Response Rate (ORR)	through study completion, an average of 2 years
Disease Control Rate (DCR)	through study completion, up to 2 years
Duration of Response (DoR)	through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: Anhui Provincial Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): June 6, 2026
• Primary Completion (Estimated): March 6, 2029
• Study Completion (Estimated): May 6, 2031

Study Registration Dates

• First Submitted: April 17, 2026
• First Submitted That Met QC Criteria: June 18, 2026
• First Posted (Actual): June 22, 2026

Study Record Updates

• Last Update Posted (Actual): June 22, 2026
• Last Update Submitted That Met QC Criteria: June 18, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung
• Other Study ID Numbers: 2026-LLYJ-0007

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No